FOLH1 and neuroblastoma: Treatments for which the Always/Majority frequency was higher than 75% were 177Lu-PSMA (88%), 90Y PRRT (83%), 32P sodium-phosphate (83%), 131I-mIBG for neuroblastoma (82%), 177Lu PRRT (79%), 131I-mIBG for adult neuroendocrine tumors (77%), and 90Y microspheres of resin (84%) and glass (78%).